TrialBMC endocrine disorders2021

Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies.

Bin Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.